Ona Therapeutics is at the forefront of developing innovative antibody drug conjugates (ADCs) specifically designed to target advanced cancer. Their approach leverages a deep understanding of the unique biology associated with treatment-refractory cancer patients, allowing them to identify novel therapeutic targets. By collaborating with leading academics and clinicians, Ona Therapeutics aims to create precision ADCs that not only address the complexities of advanced cancer but also provide effective treatment options for patients who have exhausted other therapies. Their strategy includes analyzing real-world samples from refractory patients to understand how standard treatments alter cancer at the molecular level, thereby enabling the identification of new therapeutic targets beyond traditional tumor antigens.

The company’s development process emphasizes the efficient pairing of disease biology with therapeutic mechanisms, focusing on precision targeting and antibody customization. Ona Therapeutics employs advanced engineering techniques to optimize the pharmacokinetics and tolerability of their ADCs, ensuring maximum therapeutic benefit. Their pipeline includes promising candidates such as ONA-255, aimed at breast cancer and solid tumors, and ONA-036, a monoclonal antibody targeting CD36, which plays a role in cancer progression. Through this meticulous approach, Ona Therapeutics aspires to deliver groundbreaking therapies that significantly improve outcomes for patients facing advanced cancer.

Spain

Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

Ona Therapeutics

Company Details